News

Filter

Current filters:

None

7921 to 7930 of 96155 results

Shire buys rights to arGEN-X technology for rare diseases

01-03-2012

Dutch/Belgian preclinical stage biotech company arGEN-X, focused on the discovery and development of…

BiotechnologyLicensingPharmaceuticalRare diseases

Dompe to acquire 100% control of Anabasis

01-03-2012

Italian biopharmaceutical firm Dompe has entered into a definitive agreement to acquire 100% of Anabasis…

BiotechnologyMergers & AcquisitionsOphthalmics

FDA OKs first quadrivalent flu vaccine; and lower dose Angeliq

01-03-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) US unit MedImmune's FluMist Quadrivalent, a vaccine to…

Anti-viralsNorth AmericaPharmaceuticalRegulationVaccinesWomen's Health

Nektar sells Cimzia and Mircera royalty rights for $124 million

01-03-2012

US biotech firm Nektar Therapeutics (Nasdaq: NKTR) has agreed to sell to Royalty Pharma its royalties…

Anti-Arthritics/RheumaticsBiotechnologyLicensingNephrology and Hepatology

Bayer still aims for top-10 position in Pharma

01-03-2012

Germany's Bayer (BAY: DE) is still confident that it can become a top-10 gobal pharmaceutical company,…

Markets & MarketingMergers & AcquisitionsPharmaceuticalResearch

Dainippon Sumitomo to acquire Boston Biomedical

01-03-2012

Japanese drugmaker Dainippon Sumitomo Pharma (4506: JP) says it has reached an agreement for the acquisition…

BiotechnologyMergers & AcquisitionsOncologyPharmaceutical

Forest Labs, Gedeon Richter plan 2012 filing for cariprazine

29-02-2012

Positive results from two phase III trials of Forest Laboratories and Gedeon Richter's new antipsychotic…

cariprazineForest LaboratoriesGedeon RichterHomeLexaproNamendaNeurologicalPharmaceutical

FDA expands on cholesterol-lowering drug risks

29-02-2012

Important safety changes to the labeling for some widely used cholesterol-lowering drugs known as statins…

AstraZenecaCardio-vascularCrestorLipitorMerck & CoNorth AmericaPfizerPharmaceuticalRegulationZocor

7921 to 7930 of 96155 results

Back to top